Koers Bafna Pharmaceuticals Limited NSE India S.E.
Aandelen
BAFNAPH
INE878I01014
Farmaceutische producten
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- INR | -.--% | +697,75% | +207,36% |
Omzet 2022 | 851 mln. 10,21 mln. 9,55 mln. | Omzet 2023 | 1,15 mld. 13,84 mln. 12,93 mln. | Marktkapitalisatie | 1,94 mld. 23,27 mln. 21,75 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 51 mln. 612K 572K | Nettowinst (verlies) 2023 | 113 mln. 1,36 mln. 1,27 mln. | EV/omzet 2022 | 3,65 x |
Nettoschuld 2022 | 109 mln. 1,31 mln. 1,22 mln. | Nettoschuld 2023 | 151 mln. 1,81 mln. 1,69 mln. | EV/omzet 2023 | 1,81 x |
K/w-verhouding 2022 |
58,4
x | K/w-verhouding 2023 |
17,1
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 10,23% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 62 | 01-01-81 | |
M. Sridhar
DFI | Director of Finance/CFO | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 62 | 01-01-81 | |
Krishna Yeachuri
BRD | Director/Board Member | 63 | 26-06-23 |
Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,62% | 43,34 mld. | |
+20,44% | 21,96 mld. | |
+10,86% | 14,09 mld. | |
+13,07% | 13,64 mld. | |
+37,46% | 11,43 mld. | |
-8,59% | 6,86 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+8,46% | 5,22 mld. |
- Beurs
- Aandelen
- Koers BAFNAPH
- Koers BAFNAPH